Meta‐Analysis: <scp>PPAR</scp> Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis

PPAR agonists, notably bezafibrate and seladelpar, reduce pruritus severity in PBC patients with moderate-to-severe symptoms and consistently improve itch-specific outcomes. However, effects on global HRQoL remain uncertain. These findings underscore the incorporation of validated, symptom-focused endpoints in future PBC trials.